Barbara Owczarczak

TL;DR: The ability of PDT using the second-generation photosensitiser 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) to induce proinflammatory cytokines and chemokines, as well as adhesion molecules, known to be involved in neutrophil migration is examined, in mice.

TL;DR: It is demonstrated in a BALB/c mouse model that PDT delivered to normal and tumor tissue in vivo causes marked changes in the expression of cytokines interleukin (IL)-6 and IL-10 but not tumor necrosis factor alpha, and suggested that the general inflammatory response to PDT may be mediated at least in part by IL-6.

TL;DR: It is hypothesized that PDT generated inflammatory mediators and components released from tumor cells killed by PDT results in the activation of APCs capable of stimulating effector T‐cell proliferation and cytokine secretion.

TL;DR: Results suggest that local PDT treatment of tumour treatment lead to induction of an anti-tumour immune response capable of controlling the growth of tumours outside the treatment field and indicate that this modality has potential in the treatment of distant stage disease.

TL;DR: A two-step combination therapy in which a tumor-controlling PDT regimen was combined with an immune-enhancing PDT regimen resulted in enhanced tumor-specific T cell activation and controlled metastatic tumor growth, suggesting that PDT may be an effective adjuvant for therapies that fail to stimulate the host anti-tumor immune response.